CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
Washington University School of Medicine
Neonc Technologies, Inc.
AstraZeneca
Mayo Clinic
University of Pittsburgh
National Taiwan University Hospital
University of Southampton